Filing Flows › Medifast (MED) › Q3 2026 › vs Q3 2025
Medifast (MED) Q3 2026 vs Q3 2025 (year over year)
Medifast's revenue fell $17.4M (-19%) from $89.4M in Q3 2025 to $72.0M in Q3 2026.
Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 4.0% | 12.0% | -8.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $72.0M | $89.4M | −$17.4M | -19% |
| Other income, net | $1.5M | $1.4M | $99K | +7% |
| Income tax benefit | $324K | $396K | −$72K | -18% |
| Net loss | $17.5M | $2.3M | $15.2M | +674% |
| Costs & expenses | $91.4M | $93.5M | −$2.1M | -2% |
| Operating costs | $91.4M | $93.5M | −$2.1M | -2% |
| Cost of revenue | $22.0M | $27.2M | −$5.2M | -19% |
| Operating expenses | $69.4M | $66.2M | $3.2M | +5% |
| Operating cash sources | $20.8M | $14.4M | $6.4M | +45% |
| Depreciation & amortization | $2.4M | $3.5M | −$1.1M | -32% |
| Share-based compensation | $1.9M | $910K | $940K | +103% |
| Working capital & other | $16.6M | $10.0M | $6.6M | +66% |
| Net loss absorbed | $17.5M | $2.3M | $15.2M | +674% |
| Operating cash flow | $3.3M | $12.1M | −$8.8M | -73% |
| Free cash flow (OCF − capex) | $2.9M | $10.8M | −$7.9M | -73% |
| Capital expenditures | $427K | $1.4M | −$936K | -69% |
Questions
How much did Medifast's revenue grow year over year in Q3 2026?
Medifast's revenue fell $17.4M (-19%) from $89.4M in Q3 2025 to $72.0M in Q3 2026.